Special Issue

State-of-the-Art Virus Research in Greece

Message from the Guest Editors

The Coronavirus pandemic, in conjunction with the recent advances in technology, boosted virus research in Greece, as worldwide. Existing state-of-the art research on viruses affecting humans, animals, plants and microorganisms joint forces in 2020 with a variety of other biomedical or non-biomedical disciplines as a response to the SARS-Cov-2 pandemic. New technologies and needs in the study of endemic and emerging infectious diseases in Greece have substantially boosted high-quality research into virology. In this Special Issue, we will focus on state-of-the-art virus research in Greece, from virus molecular biology and pathogenesis to antiviral agents and therapy.

Guest Editors

Dr. Ioannis Karakasiliotis

Prof. Dr. Apostolos Beloukas

Dr. Serafeim Chaintoutis

Deadline for manuscript submissions

closed (31 October 2022)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/85022

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

